PCM
SAGE

PenderFund Capital Management’s Sage Therapeutics SAGE Stock Holding History

PenderFund Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,300
Closed -$75.7K – 231
2025
Q2 		$75.7K Buy
+8,300
New +$61K 0.02% 118

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

PenderFund Capital Management's SAGE Position: Q3 2025 in Review

PenderFund Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 8,300 shares — an estimated $75.7K sold.

PenderFund Capital Management first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $75.7K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • PenderFund Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • PenderFund Capital Management sold 8,300 Sage Therapeutics shares in Q3 2025, an estimated $75.7K.
  • PenderFund Capital Management first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • PenderFund Capital Management's Sage Therapeutics position peaked at $75.7K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on PenderFund Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.